JNJ Stock Falls on MedTech Miss: Time to Buy the Dip?
💡 Puntos Clave
J&J's raised guidance and booming oncology business make the post-earnings dip a buying opportunity for long-term dividend investors.
J&J Beats Estimates and Raises Guidance, but MedTech Weakness Spooks Investors
Johnson & Johnson reported third-quarter revenue of $25.9 billion, up 6% year over year, and adjusted earnings per share of $2.59, down 7.5% but still ahead of analyst estimates. The company also raised its full-year 2026 sales and earnings guidance, with operational sales growth now projected at 6.4% to 6.8% and adjusted earnings growth at 2.4% to 3.3%.
Despite the beat and raise, J&J stock fell nearly 6% on Tuesday. The culprit was the medical technology division, where sales grew just 2.5% to $8.6 billion, missing consensus estimates of $8.7 billion. Management added fuel to the fire by acknowledging that MedTech performance "needs to improve" and floating the idea of spinning off its orthopedics business, DePuy Synthes, by 2027.
Investors focused on the weakness in MedTech, which accounts for about one-third of total sales and less than 20% of adjusted net income. The orthopedics unit itself is only about a quarter of the MedTech segment, so the spinoff talk may be more about streamlining than a sign of deep trouble.
Meanwhile, J&J's oncology business continues to shine, growing over 16% to $7.6 billion in the quarter. Key drugs like Darzalex, Rybrevant, and Tecvayli posted strong double-digit growth, and the company remains on track to achieve at least $50 billion in oncology sales by 2030.
The market's reaction seems to have overlooked the bigger picture: J&J is a diversified healthcare giant with a growing cancer franchise and a reliable dividend that has increased for 64 consecutive years.
Why the Sell-Off Is Overdone and the Bull Case Remains Intact
The negative reaction to J&J's MedTech miss is understandable but shortsighted. MedTech is a small part of the overall business, and the company is already taking steps to address its underperformance by considering a spinoff of DePuy Synthes. This could unlock value and allow management to focus on higher-growth areas like oncology.
Oncology is the real growth engine here. J&J's cancer drugs are delivering impressive results, and the company's goal of $50 billion in oncology revenue by 2030 looks increasingly achievable. With a robust pipeline and recent regulatory wins like the priority review for Rybrevant Faspro, J&J is positioning itself as a leader in cancer treatment.
For income investors, the dividend is a key attraction. The stock offers a forward yield of about 2%, backed by a 64-year streak of annual increases. With projected earnings of $11.10 per share this year and $11.79 next year, the dividend payout of $5.32 is well covered, leaving plenty of room for future growth.
Analysts remain bullish, with a consensus price target of $282.48, implying significant upside from current levels. The pullback provides an attractive entry point for long-term investors who value stability, growth, and a growing dividend.
Fuente: The Motley Fool
Análisis generado por el modelo cuantitativo de Bobby AI, revisado y editado por nuestro equipo de investigación. Esto no constituye asesoramiento financiero. Investigue por su cuenta antes de tomar decisiones de inversión.
Bobby Insight
Buy JNJ on the dip; the market overreacted to MedTech weakness while ignoring the company's raised outlook and oncology momentum.
J&J's diversified business and growing cancer franchise provide a solid foundation for future growth. The 64-year dividend growth streak adds stability, and analyst consensus points to significant upside. Short-term noise around MedTech should not overshadow the long-term opportunity.
¿Cómo Me Afecta?
